Abstract
Anxiety disorders are common and distressing medical conditions, which typically arise in adolescence or early adult life. They can persist for many years, reducing quality of life, limiting academic and occupational achievement, and being responsible for considerable economic pressures. Although a range of psychological and pharmacological treatments are available, their success is often limited, and many patients remain troubled by significant symptom-related disability for long periods. The detailed pathophysiology of each anxiety disorder is not established, and novel treatments that are based solely on current understanding of conventional neurotransmitter function are unlikely to be substantially more effective or better tolerated than current treatments. Investigations of hypothalamo-pituitary axis function across panic disorder, generalized anxiety disorder, specific phobias and social anxiety disorder have produced intriguing findings but not revealed a consistent pattern of endocrine disturbance, perhaps reflecting differences in methodology and the nature and size of the clinical samples. There is a persistent need for large, prospective studies using standardized methods for investigation and data analysis (164 words).
Submitted for inclusion within Bluhm and Pariante (eds) Behavioral Neurobiology of Stress-related Disorders February 2014
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Abelson JL, Curtis GC (1989) Cardiac and neuroendocrine responses to exposure therapy in height phobics: desynchrony within the physiological response system. Behav Res Ther 27:561–567
Abelson JL, Nesse RM, Vinik A (1991) Stimulation of corticotropin release by pentagastrin in normal subjects and patients with panic disorder. Biol Psychiatry 29:1220–1223
Abelson JL, Nesse RM, Vinik AI (1994) Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. Biol Psychiatry 36:84–96
Abelson JL, Curtis GC (1996a) Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-hour secretion of corticotropin and cortisol. Arch Gen Psychiatry 53:323–331
Abelson JL, Curtis GC (1996b) Hypothalamic-pituitary-adrenal axis activity in panic disorder: prediction of long-term outcome by pretreatment cortisol levels. Am J Psychiatry 153:69–73
Abelson JL, Curtis GC, Cameron OG (1996) Hypothalamic-pituitary-adrenal axis activity in panic disorder: effects of alprazolam on 24 h secretion of adrenocorticotropin and cortisol. J Psychiatr Res 30:79–93
Abelson JL, Liberzon I, Young EA et al (2005) Cognitive modulation of the endocrine stress response to a pharmacological challenge in normal and panic disorder subjects. Arch Gen Psychiatry 62:668–675
Ahs F, Furmark T, Michelgård A et al (2006) Hypothalamic blood flow correlates positively with stress-induced cortisol levels in subjects with social anxiety disorder. Psychosom Med 68:859–862
Alfano CA, Reynolds K, Scott N et al (2013) Polysomnographic sleep patterns of non-depressed, non-medicated children with generalized anxiety disorder. J Affect Disord 147(1–3):379–384
Alpers GW, Abelson JL, Wilhelm FH et al (2003) Salivary cortisol response during exposure treatment in driving phobics. Psychosom Med 65:679–687
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (DSM-5). American Psychiatric Publishing, Washington
Avery DH, Osgood TB, Ishiki DM et al (1985) The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder. Am J Psychiatry 142:844–848
Baldwin DS, Allgulander C, Altamura AC et al (2010) Manifesto for a european anxiety disorders research network. Eur Neuropsychopharmacol 20:426–432
Baldwin DS, Pallanti S, Zwanzger P (2013) Develo** a european research network to address unmet needs in anxiety disorders. Neurosci Biobehav Rev 37:2312–2317
Bandelow B, Sengos G, Wedekind D et al (1997) Urinary excretion of cortisol, norepinephrine, testosterone, and melatonin in panic disorder. Pharmacopsychiatry 30:113–117. Erratum in: Pharmacopsychiatry 1997 30, 278
Bandelow B, Wedekind D, Pauls J et al (2000a) Salivary cortisol in panic attacks. Am J Psychiatry 157:454–456
Bandelow B, Wedekind D, Sandvoss V et al (2000b) Diurnal variation of cortisol in panic disorder. Psychiatry Res 95:245–250
Belgorodsky A, Knyazhansky L, Loewenthal U et al (2005) Effects of the cortisol synthesis inhibitor metyrapone on the response to carbon dioxide challenge in panic disorder. Depress Anxiety 21:143–148. Erratum in: Depress Anxiety 2005 21:203
Brambilla F, Bellodi L, Perna G et al (1992) Psychoimmunoendocrine aspects of panic disorder. Neuropsychobiol 26:12–22
Brambilla F, Bellodi L, Arancio C et al (1995) Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. Psychoneuroendocrinol 20:11–19
Brand S, Annen H, Holsboer-Trachsler E et al (2011) Intensive 2-day cognitive-behavioral intervention decreases cortisol secretion in soldiers suffering from specific phobia to wear protective mask. J Psychiatr Res 45:1337–1345
Bridges M, Yeragani VK, Rainey JM et al (1986) Dexamethasone suppression test in patients with panic attacks. Biol Psychiatry 21(8–9):853–855
Broocks A, Bandelow B, George A et al (2000) Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int Clin Psychopharmacol 15:153–161
Broocks A, Bandelow B, Koch K et al (2002) Smoking modulates neuroendocrine responses to ipsapirone in patients with panic disorder. Neuropsychopharmacol 27:270–278
Broocks A, Meyer T, Opitz M et al (2003) 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo. Eur Neuropsychopharmacol 13:153–164
Carson SW, Halbreich U, Yeh CM et al (1988) Altered plasma dexamethasone and cortisol suppressibility in patients with panic disorders. Biol Psychiatry 24:56–62
Charney DS, Heninger GR, Jatlow PI (1985) Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 42:233–243
Charney DS, Woods SW, Goodman WK et al (1987a) Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 144:1030–1036
Charney DS, Woods SW, Goodman WK et al (1987b) Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacol 92:14–24
Chaudieu I, Beluche I, Norton J et al (2008) Abnormal reactions to environmental stress in elderly persons with anxiety disorders: evidence from a population study of diurnal cortisol changes. J Affect Disord 106:307–313
Cohn JB, Wilcox CS, Meltzer HY (1986) Neuroendocrine effects of buspirone in patients with generalized anxiety disorder. Am J Med 80(3B):36–40
Coplan JD, Papp LA, Pine D et al (1997) Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder. Arch Gen Psychiatry 54:643–648
Coplan JD, Goetz R, Klein DF et al (1998) Plasma cortisol concentrations preceding lactate-induced panic. Psychological, biochemical, and physiological correlates. Arch Gen Psychiatry 55:130–136
Coryell W, Noyes R Jr, Clancy J et al (1985) Abnormal escape from dexamethasone suppression in agoraphobia with panic attacks. Psychiatry Res 15:301–311
Coryell W, Noyes R (1988) HPA axis disturbance and treatment outcome in panic disorder. Biol Psychiatry 24:762–766
Coryell W, Noyes R Jr, Schlechte J (1989) The significance of HPA axis disturbance in panic disorder. Biol Psychiatry 25:989–1002
Coryell W, Noyes R Jr, Reich J (1991) The prognostic significance of HPA-axis disturbance in panic disorder: a 3-year follow-up. Biol Psychiatry 29:96–102
Cottraux J, Claustrat B 91984) The dexamethasone suppression test in agoraphobia with panic attacks. 30 cases. Encephale 10:267–272 (French)
Curtis GC, Abelson JL, Gold PW (1997) Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. Biol Psychiatry 41:76–85
Den Boer JA, Westenberg HG (1990) Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 102:85–94
de Quervain DJ, Margraf J (2008) Glucocorticoids for the treatment of post-traumatic stress disorder and phobias: a novel therapeutic approach. Eur J Pharmacol 583:365–371
de Quervain DJ, Bentz D, Michael T et al (2011) Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci USA 108:6621–6625
DeVane CL, Ware MR, Emmanuel NP et al (1999) Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia. Int Clin Psychopharmacol 14:345–351
Dorn LD, Burgess ES, Friedman TC et al (1997) The longitudinal course of psychopathology in Cushing’s syndrome after correction of hypercortisolism. J Clin Endocrinol Metab 82:912–919
Erhardt A, Ising M, Unschuld PG et al (2006) Regulation of the hypothalamic-pituitary-adrenocortical system in patients with panic disorder. Neuropsychopharmacol 31:2515–2522
Essex MJ, Klein MH, Slattery MJ et al (2010) Early risk factors and developmental pathways to chronic high inhibition and social anxiety disorder in adolescence. Am J Psychiatry 167:40–46
Faludi G, Kaskó M, Perényi A et al (1986) The dexamethasone suppression test in panic disorder and major depressive episodes. Biol Psychiatry 21:1008–1014
Fava M, Rosenbaum JF, MacLaughlin RA et al (1989) Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder. Psychiatry Res 28:345–350
Fredrikson M, Sundin O, Frankenhaeuser M (1985) Cortisol excretion during the defense reaction in humans. Psychosom Med 47:313–319
Furlan PM, DeMartinis N, Schweizer E et al (2001) Abnormal salivary cortisol levels in social phobic patients in response to acute psychological but not physical stress. Biol Psychiatry 50:254–259
Garcia-Leal C, Parente AC, Del-Ben CM et al (2005) Anxiety and salivary cortisol in symptomatic and nonsymptomatic panic patients and healthy volunteers performing simulated public speaking. Psychiatry Res 133:239–252
Germine M, Goddard AW, Sholomskas DE et al (1994) Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res 54:115–133
Gerra G, Zaimovic A, Zambelli U et al (2000) Neuroendocrine responses to psychological stress in adolescents with anxiety disorder. Neuropsychobiol 42:82–92
Goldstein S, Halbreich U, Asnis G et al (1987) The hypothalamic-pituitary-adrenal system in panic disorder. Am J Psychiatry 144:1320–1323
Grunhaus L, Tiongco D, Haskett RF et al (1987) The dexamethasone suppression test in inpatients with panic disorder or agoraphobia with panic attacks. Biol Psychiatry 22:517–521
Hek K, Direk N, Newson RS et al (2013) Anxiety disorders and salivary cortisol levels in older adults: a population-based study. Psychoneuroendocrinol 38:300–305
Herbert J, Goodyer IM, Altham PM et al (1996) Adrenal secretion and major depression in 8–16-year-olds, II. Influence of co-morbidity at presentation. Psychol Med 26:257–263
Herrán A, Sierra-Biddle D, GarcÃa-Unzueta MT et al (2005) The acute phase response in panic disorder. Int J Neuropsychopharmacol 8:529–535
Hoehn-Saric R, McLeod DR, Lee YB et al (1991) Cortisol levels in generalized anxiety disorder. Psychiatry Res 38:313–315
Hollander E, Liebowitz MR, Gorman JM et al (1989) Cortisol and sodium lactate-induced panic. Arch Gen Psychiatry 46:135–140
Hollander E, Kwon J, Weiller F et al (1998) Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects. Psychiatry Res 79:213–217
Hood SD, Hince DA, Robinson H et al (2006) Serotonin regulation of the human stress response. Psychoneuroendocrinol 31:1087–1097
Jezova D, Vigas M, Hlavacova N et al (2010) Attenuated neuroendocrine response to hypoglycemic stress in patients with panic disorder. Neuroendocrinol 92:112–119
Judd FK, Norman TR, Burrows GD et al (1987) The dexamethasone suppression test in panic disorder. Pharmacopsychiatry 20:99–101
Judd FK, Apostolopoulos M, Burrows GD (1994) Serotonergic function in panic disorder: endocrine responses to D-fenfluramine. Prog Neuropsychopharmacol Biol Psychiatry 18:329–337
Kahn RS, Asnis GM, Wetzler S et al (1988) Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology 96:360–364
Kallen VL, Tulen JH, Utens EM et al (2008) Associations between HPA axis functioning and level of anxiety in children and adolescents with an anxiety disorder. Depress Anxiety 25:131–141
Kathol RG, Noyes R Jr, Lopez AL et al (1988) Relationship of urinary free cortisol levels in patients with panic disorder to symptoms of depression and agoraphobia. Psychiatry Res 24:211–221
Kathol RG, Anton R, Noyes R et al (1989) Direct comparison of urinary free cortisol excretion in patients with depression and panic disorder. Biol Psychiatry 25:873-878
Katzman MA, Koszycki D, Bradwejn J (2004) Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder. Depress Anxiety 20:51–58
Kellner M, Yassouridis A, Jahn H et al (1997) Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder. Psychopharmacology 133:55–61
Kellner M, Knaudt K, Jahn H et al (1998) Atrial natriuretic hormone in lactate-induced panic attacks: mode of release and endocrine and pathophysiological consequences. J Psychiatr Res 32:37–48
Kellner M, Schick M, Yassouridis A et al (2004) Metyrapone tests in patients with panic disorder. Biol Psychiatry 56:898–900
Klein E, Zinder O, Colin V et al (1995) Clinical similarity and biological diversity in the response to alprazolam in patients with panic disorder and generalized anxiety disorder. Acta Psychiatr Scand 92:399–408
Knopf K, Pössel P (2009) Individual response differences in spider phobia: comparing phobic and non-phobic women of different reactivity levels. Anxiety Stress Co** 22:39–55
Krämer M, Seefeldt WL, Heinrichs N et al (2012) Subjective, autonomic, and endocrine reactivity during social stress in children with social phobia. J Abnorm Child Psychol 40:95–104
Lanzenberger R, Wadsak W, Spindelegger C et al (2010) Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. Int J Neuropsychopharmacol 13:1129–1143
Laufer N, Maayan R, Hermesh H et al (2005) Involvement of GABAA receptor modulating neuroactive steroids in patients with social phobia. Psychiatry Res 137:131–136. Erratum in: Psychiatry Res 144:95
Lenze EJ, Mantella RC, Shi P et al (2011) Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram. Am J Geriatr Psychiatry 19:482–490
Lenze EJ, Dixon D, Mantella RC et al (2012) Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder. Int J Geriatr Psychiatry 27:454–462
Lesch KP, Wiesmann M, Hoh A et al (1992) 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology 106:111–117
Levin AP, Doran AR, Liebowitz MR et al (1987) Pituitary adrenocortical unresponsiveness in lactate-induced panic. Psychiatry Res 21:23–32
Lieberman JA, Brenner R, Lesser M et al (1983) Dexamethasone suppression tests in patients with panic disorder. Am J Psychiatry 140:917–919
Liebowitz MR, Gorman JM, Fyer AJ et al (1985) Lactate provocation of panic attacks. II. Biochemical and physiological findings. Arch Gen Psychiatry 42:709–719
Lilliecreutz C, Theodorsson E, Sydsjö G et al (2011) Salivary cortisol in pregnant women suffering from blood and injection phobia. Arch Womens Ment Health 14:405–411
Lopez AL, Kathol RG, Noyes R Jr (1990) Reduction in urinary free cortisol during benzodiazepine treatment of panic disorder. Psychoneuroendocrinol 15:23–28
Loosen PT, Chambliss B, DeBold CR et al (1992) Psychiatric phenomenology in Cushing’s disease. Pharmacopsychiatry 25:192–198
Maddock RJ, Carter CS, Gietzen DW (1991) Elevated serum lactate associated with panic attacks induced by hyperventilation. Psychiatry Res 38:301–311
Martel FL, Hayward C, Lyons DM et al (1999) Salivary cortisol levels in socially phobic adolescent girls. Depress Anxiety 10:25–27
Nesse RM, Cameron OG, Curtis GC et al (1984) Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry 41:771–776
Nesse RM, Curtis GC, Thyer BA et al (1985) Endocrine and cardiovascular responses during phobic anxiety. Psychosom Med 47:320–332
Pariante CM (2009) Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressants and glucocorticoids. Ann NY Acad Sci 1179:144–152
Peskind ER, Jensen CF, Pascualy M et al (1998) Sodium lactate and hypertonic sodium chloride induce equivalent panic incidence, panic symptoms, and hypernatremia in panic disorder. Biol Psychiatry 44:1007–1016
Peterson GA, Ballenger JC, Cox DP et al (1985) The dexamethasone suppression test in agoraphobia. J Clin Psychopharmacol 5:100–102
Petrowski K, Herold U, Joraschky P et al (2010) A striking pattern of cortisol non-responsiveness to psychosocial stress in patients with panic disorder with concurrent normal cortisol awakening responses. Psychoneuroendocrinol 35:414–421
Petrowski K, Wintermann GB, Kirschbaum C et al (2012) Dissociation between ACTH and cortisol response in DEX-CRH test in patients with panic disorder. Psychoneuroendocrinol 37:1199–1208
Petrowski K, Wintermann GB, Schaarschmidt M et al (2013) Blunted salivary and plasma cortisol response in patients with panic disorder under psychosocial stress. Int J Psychophysiol doi:pii: S0167–8760(13):00017–2. 10.1016/j.ijpsycho.2013.01.002. (Epub ahead of print)
Phillips AC, Batty GD, Gale CR et al (2011) Major depressive disorder, generalised anxiety disorder, and their comorbidity: associations with cortisol in the vietnam experience study. Psychoneuroendocrinol 36:682–690
Pomara N, Willoughby LM, Sidtis JJ et al (2005) Cortisol response to diazepam: its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder. Psychopharmacol (Berl) 178:1–8
Potts NL, Davidson JR, Krishnan KR et al (1991) Levels of urinary free cortisol in social phobia. J Clin Psychiatry 52(Suppl):41–42
Rapaport MH, Risch SC, Gillin JC et al (1991) The effects of physostigmine infusion on patients with panic disorder. Biol Psychiatry 29:658–664
Roelofs K, van Peer J, Berretty E et al (2009) Hypothalamus-pituitary-adrenal axis hyperresponsiveness is associated with increased social avoidance behavior in social phobia. Biol Psychiatry 65:336–343
Rosnick CB, Rawson KS, Butters MA et al (2013) Association of cortisol with neuropsychological assessment in older adults with generalized anxiety disorder 17:432–440
Roy-Byrne PP, Uhde TW, Post RM et al (1986) The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry 143:896–899
Roy-Byrne PP, Cowley DS, Hommer D et al (1991) Neuroendocrine effects of diazepam in panic and generalized anxiety disorders. Biol Psychiatry 30:73–80
Sasaki I, Akiyoshi J, Sakurai R, et al (1996) Carbon dioxide induced panic attack in panic disorder in Japan. Prog Neuropsychopharmacol Biol Psychiatry 20:1145–1157
Seier FE, Kellner M, Yassouridis A et al (1997) Autonomic reactivity and hormonal secretion in lactate-induced panic attacks. Am J Physiol 272(6 Pt 2):H2630–H2638
Schittecatte M, Garcia-Valentin J, Charles G et al (1995) Efficacy of the clonidine REM suppression test (CREST) to separate patients with major depression from controls; a comparison with three currently proposed biological markers of depression. J Affect Disord 33:151–157
Schruers K, van Diest R, Nicolson N et al (2002) L-5-hydroxytryptophan induced increase in salivary cortisol in panic disorder patients and healthy volunteers. Psychopharmacology 161:365–369
Schweizer EE, Swenson CM, Winokur A et al (1986) The dexamethasone suppression test in generalised anxiety disorder. Br J Psychiatry 149:320–322
Seddon K, Morris K, Bailey J et al (2011) Effects of 7.5 % CO2 challenge in generalized anxiety disorder. J Psychopharmacol 25:43–51
Sheehan DV, Claycomb JB, Surman OS et al (1983) Panic attacks and the dexamethasone suppression test. Am J Psychiatry 140:1063–1064
Shlik J, Aluoja A, Vasar V et al (1997) Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22:332–340
Shlik J, Maron E, Tru I et al (2004) Citalopram challenge in social anxiety disorder. Int J Neuropsychopharmacol 7:177–182
Sinha SS, Coplan JD, Pine DS et al (1999) Panic induced by carbon dioxide inhalation and lack of hypothalamic-pituitary-adrenal axis activation. Psychiatry Res 86:93–98
Siegmund A, Köster L, Meves AM et al (2011) Stress hormones during flooding therapy and their relationship to therapy outcome in patients with panic disorder and agoraphobia. J Psychiatr Res 45:339–346
Soravia LM, Heinrichs M, Aerni A et al (2006) Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci U S A 103:5585–5590
Staufenbiel SM, Penninx BW, Spijker AT et al (2013) Hair cortisol, stress exposure, and mental health in humans: a systematic review. Psychoneuroendocrinol 38:1220–1235
Stein MB, Uhde TW (1988) Cortisol response to clonidine in panic disorder: comparison with depressed patients and normal controls. Biol Psychiatry 24:322–330
Steudte S, Stalder T, Dettenborn L et al (2011) Decreased hair cortisol concentrations in generalised anxiety disorder. Psychiatry Res 186(2–3):310–314
Stones A, Groome D, Perry D et al (1999) The effect of stress on salivary cortisol in panic disorder patients. J Affect Disord 52(1–3):197–201
Ströhle A, Kellner M, Yassouridis A et al (1998) Effect of flumazenil in lactate-sensitive patients with panic disorder. Am J Psychiatry 155:610–612
Ströhle A, Holsboer F, Rupprecht R (2000) Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacol 22:251–256
Tafet GE, Idoyaga-Vargas VP, Abulafia DP et al (2001) Correlation between cortisol level and serotonin uptake in patients with chronic stress and depression. Cogn Affect Behav Neurosci 1:388–393
Tafet GE, Feder DJ, Abulafia DP et al (2005) Regulation of hypothalamic-pituitary-adrenal activity in response to cognitive therapy in patients with generalized anxiety disorder. Cogn Affect Behav Neurosci 5:37–40
Tancer ME, Mailman RB, Stein MB et al (1994–1995) Neuroendocrine responsivity to monoaminergic system probes in generalized social phobia. Anxiety 1:216–223
Targum SD, Marshall LE (1989) Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 28:295–306
Targum SD (1990) Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder. Biol Psychiatry 28:21–34
Tiller JW, Biddle N, Maguire KP et al (1988) The dexamethasone suppression test and plasma dexamethasone in generalized anxiety disorder. Biol Psychiatry 23:261–270
Uhde TW, Joffe RT, Jimerson DC et al (1988) Normal urinary free cortisol and plasma MHPG in panic disorder: clinical and theoretical implications. Biol Psychiatry 23:575–585
Uhde TW, Tancer ME, Gelernter CS et al (1994) Normal urinary free cortisol and postdexamethasone cortisol in social phobia: comparison to normal volunteers. J Affect Disord 30:155–161
van der Wee NJ, Fiselier J, van Megen HJ et al (2004) Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine in patients with panic disorder and controls. Eur Neuropsychopharmacol 14:413–417
van Duinen MA, Schruers KR, Jaegers E et al (2004) Salivary cortisol in panic: are males more vulnerable? Neuro Endocrinol Lett 25:386–390
van Duinen MA, Schruers KR, Maes M et al (2005) CO2 challenge results in hypothalamic-pituitary-adrenal activation in healthy volunteers. J Psychopharmacol 19:243–247
van Duinen MA, Schruers KR, Maes M et al (2007) CO2 challenge induced HPA axis activation in panic. Int J Neuropsychopharmacol 10:797–804
van Duinen MA, Schruers KR, Griez EJ (2010) Desynchrony of fear in phobic exposure. J Psychopharmacol 24:695–699
van Megen HJ, Westenberg HG, Den Boer JA et al (1996) The panic-inducing properties of the cholecystokinin tetrapeptide CCK4 in patients with panic disorder. Eur Neuropsychopharmacol 6:187–194
van Peer JM, Spinhoven P, van Dijk JG et al (2009) Cortisol-induced enhancement of emotional face processing in social phobia depends on symptom severity and motivational context. Biol Psychol 81:123–130
Van Veen JF, Van der Wee NJ, Fiselier J et al (2007) Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls. Eur Neuropsychopharmacol 17:637–642
van Peer JM, Spinhoven P, Roelofs K (2010) Psychophysiological evidence for cortisol-induced reduction in early bias for implicit social threat in social phobia. Psychoneuroendocrinol 35:21–32
van Veen JF, van Vliet IM, Derijk RH et al (2008) Elevated alpha-amylase but not cortisol in generalized social anxiety disorder. Psychoneuroendocrinol 33:1313–1321
van Veen JF, van Vliet IM, de Rijk RH et al (2009) Tryptophan depletion affects the autonomic stress response in generalized social anxiety disorder. Psychoneuroendocrinol 34:1590–1594
van Vliet IM, Slaap BR, Westenberg HG et al (1996) Behavioral, neuroendocrine and biochemical effects of different doses of 5-HTP in panic disorder. Eur Neuropsychopharmacol 6:103–110
van West D, Claes S, Sulon J et al (2008) Hypothalamic-pituitary-adrenal reactivity in prepubertal children with social phobia. J Affect Disord 111:281–290
Villacres EC, Hollifield M, Katon WJ et al (1987) Sympathetic nervous system activity in panic disorder. Psychiatry Res 21:313–321
Vreeburg SA, Zitman FG, van Pelt J et al (2010) Salivary cortisol levels in persons with and without different anxiety disorders. Psychosom Med 72:340–347
Wedekind D, Bandelow B, Broocks A et al (2000) Salivary, total plasma and plasma free cortisol in panic disorder. J Neural Trans 107:831–837
Wedekind D, Sprute A, Broocks A et al (2008) Nocturnal urinary cortisol excretion over a randomized controlled trial with paroxetine vs. placebo combined with relaxation training or aerobic exercise in panic disorder. Curr Pharm Des 14:3518–3524
Westberg P, Modigh K, Lisjö P et al (1991) Higher postdexamethasone serum cortisol levels in agoraphobic than in nonagoraphobic panic disorder patients. Biol Psychiatry 30:247–256
Wetzler S, Asnis GM, DeLecuona JM et al (1996) Serotonin function in panic disorder: intravenous administration of meta-chlorophenylpiperazine. Psychiatry Res 64:77–82
Westenberg HG, den Boer JA (1989) Serotonin function in panic disorder: effect of 1-5-hydroxytryptophan in patients and controls. Psychopharmacology 98:283–285
Whiteford HA, Evans L (1984) Agoraphobia and the dexamethasone suppression test: atypical depression? Aust N Z J Psychiatry 18:374–377
Wiedemann K, Jahn H, Yassouridis A et al (2001) Anxiolytic-like effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Arch Gen Psychiatry 58:371–377
Woods SW, Charney DS, McPherson CA et al (1987) Situational panic attacks. Behavioral, physiologic, and biochemical characterization. Arch Gen Psychiatry 44:365–375
Acknowledgments
Hesham Yousry Elnazer receives a bursary from KSS Deanery to support his postgraduate doctorate studies. David Baldwin chairs the Anxiety Disorders Research Network (ADRN) within the European College of Neuropsychopharmacology Network Initiative (ECNP-NI), and the University Department of Psychiatry in Southampton receives funding from the ECNP-NI for administrative support designed to foster the further development of the ADRN.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Elnazer, H.Y., Baldwin, D.S. (2014). Investigation of Cortisol Levels in Patients with Anxiety Disorders: A Structured Review. In: Pariante, C., Lapiz-Bluhm, M. (eds) Behavioral Neurobiology of Stress-related Disorders. Current Topics in Behavioral Neurosciences, vol 18. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2014_299
Download citation
DOI: https://doi.org/10.1007/7854_2014_299
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-45125-0
Online ISBN: 978-3-662-45126-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)